| Open Study of the Duration of Immunity After Vaccination With GamEvac (NCT02911428) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2016-10-01 |
| Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo (NCT02598388) | Janssen Vaccines & Prevention B.V. | 2015-12-10 |
| Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults (NCT02564523) | Janssen Vaccines & Prevention B.V. | 2015-11-06 |
| Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults (NCT02564575) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-08-01 |
| STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) (NCT02378753) | Centers for Disease Control and Prevention | 2015-04-01 |
| Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea (NCT02342171) | Institute of Tropical Medicine, Belgium | 2015-02-01 |
| Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda (NCT02354404) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-01-27 |
| Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) (NCT02283099) | Universitätsklinikum Hamburg-Eppendorf | 2014-11-01 |
| Experimental Ebola Vaccine Trial (NCT00072605) | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-10-30 |